利多卡因联用对行包皮环切术患儿所需艾司氯胺酮半数有效量的影响

doi:10.3969/j.issn.1674-8115.2022.12.008

摘要/Abstract

摘要：

目的·探索利多卡因联用对行包皮环切术所需艾司氯胺酮半数有效量（median effective dose，ED₅₀）的影响，评估其对儿童心血管的稳定性。方法·采用序贯法纳入上海交通大学医学院附属上海儿童医学中心2021年4月—6月在艾司氯胺酮静脉麻醉下行包皮环切术的3~7岁患儿，艾司氯胺酮给药后静脉注射0.5%利多卡因1.5 mg/kg再行手术，计算与利多卡因联用时行儿童包皮环切术所需的艾司氯胺酮ED₅₀，并观察患儿用药后的起效时间、苏醒时间、生命体征［心率、脉氧饱和度（SpO₂）、平均动脉压］变化以及不良反应。使用Dixon法取交叉点数据计算艾司氯胺酮ED₅₀，使用概率回归法计算艾司氯胺酮ED₅₀、95%有效剂量（ED₉₅）及其95%可信区间。组间一般资料的比较使用单因素ANOVA，组间起效时间、苏醒时间、各时间节点（静脉注射咪达唑仑后3 min、静脉注射艾司氯胺酮后3 min、手术切皮、手术结束）的生命体征（心率、SpO₂、平均动脉压）的比较使用独立样本t检验；各组所需的艾司氯胺酮ED₅₀的比较使用Mann-Whitney U检验。结果·艾司氯胺酮与利多卡因联用时，行包皮环切术所需ED₅₀为1.55 mg/kg（95%CI 1.47~1.63）。与前期开展的艾司氯胺酮单药用于儿童包皮环切术的研究数据［ED₅₀=1.90 mg/kg（95% CI 1.75~2.05）］相比，两者联用时行包皮环切术所需的艾司氯胺酮ED₅₀显著降低（P=0.001），术中的平均动脉压均显著低于艾司氯胺酮单药组（P=0.000，P=0.004，P=0.010）。两药联用时对心率无明显影响，部分患儿的SpO₂有一过性降低。结论·艾司氯胺酮与利多卡因联用能够显著降低儿童包皮环切术所需的艾司氯胺酮ED₅₀，术中血压更平稳，但对呼吸可能存在一过性抑制。

关键词: 艾司氯胺酮, 利多卡因, 儿童, 包皮环切术, 半数有效量

Abstract:

Objective ·To evaluate the median effective dose (ED₅₀) and cardiovascular stability of esketamine in combination with lidocaine for pediatric patients undergoing circumcision. Methods ·Children aged 3?7 years selected for circumcision between April and June 2021 in Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicinewere enrolled in this study. All children enrolled were administrated 0.5% lidocaine 1.5 mg/kg intravenously after anesthesia was induced by esketamine. The ED₅₀ of esketamine required for children undergoing circumcision was determined by Dixon's up-and-down method, which calculated the mean of the crossover midpoints. Additionally, ED₅₀ and ED₉₅ of esketamine were estimated by probit regression. Onset time, wake-up time, vital signs including heart rate, pulse oxygen saturation and mean artery pressure, and adverse events were recorded. Differences in age, weight of the patients between the two groups were compared by one-way ANOVA. Differences in onset time, wake-up time, and vital signs including heart rate, pulse oxygen saturation (SpO₂) and mean arterial pressure in each time point between the two groups were compared by using the independent samples t-test. The ED₅₀ values of esketamine was compared between the two groups by Mann-Whitney U test. Results ·When administrated in combination with lidocaine, the ED₅₀ of esketamine for children undergoing circumcision was 1.55 mg/kg (95% CI 1.47?1.63). Compared to the data of our previous study, the ED₅₀ of esketamine required for children undergoing circumcision in combination with lidocaine was significantly lower than that of esketamine solo agent [ED₅₀=1.90 mg/kg (95% CI 1.75?2.05)] (P=0.001). The mean arterial pressure of children pretreated with lidocaine was significantly lower than that of esketamine solo agent at each time point during the surgery (P=0.000, P=0.004, P=0.010), and no significant effect on heart rate was observed. A transient decrease in SpO₂ was observed when esketamine was used in combination with lidocaine. Conclusion ·Anesthesia induced by esketamine combined with lidocaine can significantly reduce the ED₅₀ of esketamine required for pediatric patients undergoing circumcision, and better stability of blood pressure is achieved. However, transient respiratory depression should be noted.

Key words: esketamine, lidocaine, children, circumcision, median effective dose

中图分类号:

R459.9

李波, 朱明, 郑吉建. 利多卡因联用对行包皮环切术患儿所需艾司氯胺酮半数有效量的影响[J]. 上海交通大学学报（医学版）, 2022, 42(12): 1706-1711.

LI Bo, ZHU Ming, ZHENG Jijian. Effect of lidocaine on median effective dose of esketamine for children undergoing circumcision[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(12): 1706-1711.

图/表 6

参考文献 25

1	PELTONIEMI M A, HAGELBERG N M, OLKKOLA K T, et al. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy[J]. Clin Pharmacokinet, 2016, 55(9): 1059-1077.
2	李波, 朱明, 但颖之, 等. 艾司氯胺酮单药或联合小剂量阿片类药物用于儿童包皮环切术的半数有效剂量研究[J]. 上海医学, 2021, 44(3): 177-182.
	LI B, ZHU M, DAN Y Z, et al. Median effective dose of esketamine solo or in combination with low-dose opioids for pediatric patients undergoing circumcision[J]. Shanghai Med J, 2021, 44(3): 177-182.
3	TRIMMEL H, HELBOK R, STAUDINGER T, et al. S(+)-ketamine: current trends in emergency and intensive care medicine[J]. Wien Klin Wochenschr, 2018, 130(9/10): 356-366.
4	BEAUSSIER M, DELBOS A, MAURICE-SZAMBURSKI A, et al. Perioperative use of intravenous lidocaine[J]. Drugs, 2018, 78(12): 1229-1246.
5	GÖRGES M, ZHOU G H, BRANT R, et al. Sequential allocation trial design in anesthesia: an introduction to methods, modeling, and clinical applications[J]. Paediatr Anaesth, 2017, 27(3): 240-247.
6	PACE N L, STYLIANOU M P. Advances in and limitations of up-and-down methodology: a précis of clinical use, study design, and dose estimation in anesthesia research[J]. Anesthesiology, 2007, 107(1): 144-152.
7	YU Q, LIU Y, SUN M, et al. Median effective dose of intranasal dexmedetomidine sedation for transthoracic echocardiography in pediatric patients with noncyanotic congenital heart disease: an up-and-down sequential allocation trial[J]. Paediatr Anaesth, 2017, 27(11): 1108-1114.
8	BATKO I, KOŚCIELNIAK-MERAK B, TOMASIK P J, et al. Lidocaine reduces sevoflurane consumption and improves recovery profile in children undergoing major spine surgery[J]. Med Sci Monit, 2020, 26: e919971.
9	HASHEMIAN A M, ZAMANI MOGHADAM DOLOO H, SAADATFAR M, et al. Effects of intravenous administration of fentanyl and lidocaine on hemodynamic responses following endotracheal intubation[J]. Am J Emerg Med, 2018, 36(2): 197-201.
10	MAHJOUBIFARD M, HEIDARI M, DAHMARDEH M, et al. Comparison of dexmedetomidine, lidocaine, and fentanyl in attenuation hemodynamic response of laryngoscopy and intubation in patients undergoing cardiac surgery[J]. Anesthesiol Res Pract, 2020, 2020: 4814037.
11	GILBERT C R A, HANSON I R, BROWN A B, et al. Intravenous use of xylocaine[J]. Curr Res Anesth Analg, 1951, 30(6): 301-313.
12	VAN DER WAL S E I, VAN DEN HEUVEL S A S, RADEMA S A, et al. The in vitro mechanisms and in vivo efficacy of intravenous lidocaine on the neuroinflammatory response in acute and chronic pain[J]. Eur J Pain, 2016, 20(5): 655-674.
13	LEE I W S, SCHRAAG S. The use of intravenous lidocaine in perioperative medicine: anaesthetic, analgesic and immune-modulatory aspects[J]. J Clin Med, 2022, 11(12): 3543.
14	EIPE N, GUPTA S, PENNING J. Intravenous lidocaine for acute pain: an evidence-based clinical update[J]. BJA Educ, 2016, 16(9): 292-298.
15	CUI W H, LI Y P, LI S R, et al. Systemic administration of lidocaine reduces morphine requirements and postoperative pain of patients undergoing thoracic surgery after propofol-remifentanil-based anaesthesia[J]. Eur J Anaesthesiol, 2010, 27(1): 41-46.
16	BAJRACHARYA J L, SUBEDI A, POKHAREL K, et al. The effect of intraoperative lidocaine versus esmolol infusion on postoperative analgesia in laparoscopic cholecystectomy: a randomized clinical trial[J]. BMC Anesthesiol, 2019, 19(1): 198.
17	HWANG W J, MOON Y E, CHO S J, et al. The effect of a continuous infusion of low-dose esmolol on the requirement for remifentanil during laparoscopic gynecologic surgery[J]. J Clin Anesth, 2013, 25(1): 36-41.
18	ASOUHIDOU I, TRIKOUPI A. Esmolol reduces anesthetic requirements thereby facilitating early extubation; a prospective controlled study in patients undergoing intracranial surgery[J]. BMC Anesthesiol, 2015, 15: 172.
19	WATTS R, THIRUVENKATARAJAN V, CALVERT M, et al. The effect of perioperative esmolol on early postoperative pain: a systematic review and meta-analysis[J]. J Anaesthesiol Clin Pharmacol, 2017, 33(1): 28-39.
20	NAIR A. Esmolol: an avoidable agent for intraoperative use as an antinociceptive[J]. Reg Anesth Pain Med, 2019, 44(6): 683.
21	SOTO G, NARANJO GONZÁLEZ M, CALERO F. Intravenous lidocaine infusion[J]. Rev Esp Anestesiol Reanim (Engl Ed), 2018, 65(5): 269-274.
22	DE OLIVEIRA K, EIPE N. Intravenous lidocaine for acute pain: a single-institution retrospective study[J]. Drugs Real World Outcomes, 2020, 7(3): 205-212.
23	YU J S, LOUER R, LUTFI R, et al. Adjuvant lidocaine to a propofol-ketamine-based sedation regimen for bone marrow aspirates and biopsy in the pediatric population[J]. Eur J Pediatr, 2021, 180(1): 73-80.
24	FLORES-GONZÁLEZ J C, ESTALELLA-MENDOZA A, RODRÍGUEZ-CAMPOY P, et al. Topical pharyngeal lidocaine reduces respiratory adverse events during upper gastrointestinal endoscopies under ketamine sedation in children[J]. Paediatr Drugs, 2019, 21(1): 25-31.
25	KRAUSS B, GREEN S M. Procedural sedation and analgesia in children[J]. Lancet, 2006, 367(9512): 766-780.

Item	Score
State of activity
Able to move four extremities voluntarily or on command	2
Able to move two extremities voluntarily or on command	1
Able to move 0 extremities voluntarily or on command	0
State of respiration
Able to breathe deeply and cough freely	2
Dyspnea or limited breathing	1
Apnea	0
State of circulation
BP ± 20 mmHg of preanesthetic period	2
BP ± 20 to 50 mmHg of preanesthetic period	1
BP ± 50 mmHg of preanesthetic period	0
State of consciousness
Fully awake	2
Arousable on calling	1
No response	0
State of O₂ saturation
> 92% on room air	2
Needs O₂ to maintain SpO₂ > 90%	1
< 90% despite O₂ supplementation	0

Item	Score
State of activity
Able to move four extremities voluntarily or on command	2
Able to move two extremities voluntarily or on command	1
Able to move 0 extremities voluntarily or on command	0
State of respiration
Able to breathe deeply and cough freely	2
Dyspnea or limited breathing	1
Apnea	0
State of circulation
BP ± 20 mmHg of preanesthetic period	2
BP ± 20 to 50 mmHg of preanesthetic period	1
BP ± 50 mmHg of preanesthetic period	0
State of consciousness
Fully awake	2
Arousable on calling	1
No response	0
State of O₂ saturation
> 92% on room air	2
Needs O₂ to maintain SpO₂ > 90%	1
< 90% despite O₂ supplementation	0

Time point	Heart rate/beat·min^-1		SpO₂/%		MAP/mmHg
Time point	Group A	Group B	Group A	Group B	Group A	Group B
T0	89.1 ± 11.5	88.5 ± 11.3	98.8 ± 1.0	98.6 ± 1.0	75.8 ± 8.3	75.1 ± 5.3
T1	110.7 ± 10.1	105.2 ± 10.4	98.1 ± 1.9	93.8 ± 3.5^①	107.7 ± 8.5	92.8 ± 7.1^②
T2	118.5 ± 13.3	115.5 ± 11.2	99.5 ± 0.7	98.8 ± 1.0	120.0 ± 15.3	103.5 ± 9.4^③
T3	110.3 ± 9.1	112.2 ± 13.2	99.5 ± 0.7	99.5 ± 0.8	115.6 ± 11.2	104.8 ± 7.4^④

Time point	Heart rate/beat·min^-1		SpO₂/%		MAP/mmHg
Time point	Group A	Group B	Group A	Group B	Group A	Group B
T0	89.1 ± 11.5	88.5 ± 11.3	98.8 ± 1.0	98.6 ± 1.0	75.8 ± 8.3	75.1 ± 5.3
T1	110.7 ± 10.1	105.2 ± 10.4	98.1 ± 1.9	93.8 ± 3.5^①	107.7 ± 8.5	92.8 ± 7.1^②
T2	118.5 ± 13.3	115.5 ± 11.2	99.5 ± 0.7	98.8 ± 1.0	120.0 ± 15.3	103.5 ± 9.4^③
T3	110.3 ± 9.1	112.2 ± 13.2	99.5 ± 0.7	99.5 ± 0.8	115.6 ± 11.2	104.8 ± 7.4^④

[1]	罗雯懿, 陈琳, 袁理, 倪平, 蔡小满, 章雅青. 3~6岁先天性心脏病患儿术后心脏康复水平及其相关因素的Rasch分析[J]. 上海交通大学学报（医学版）, 2022, 42(9): 1303-1310.
[2]	李雯, 李苑, 叶海昀, 张笑笑, 乔彤, 李嫔. 1型糖尿病儿童眼底黄斑区早期微血管变化的观察[J]. 上海交通大学学报（医学版）, 2022, 42(9): 1311-1314.
[3]	户宜, 丁国栋. 上海地区学龄前儿童对羟基苯甲酸酯类物质暴露与肺功能的相关性研究[J]. 上海交通大学学报（医学版）, 2022, 42(8): 1103-1109.
[4]	邢正文, 吴滢, 王雪莉, 王庆煜, 王文婷, 李治, 张彬, 金晶. 儿童CIC重排肉瘤的临床病理特征[J]. 上海交通大学学报（医学版）, 2022, 42(8): 1151-1157.
[5]	邢正文, 吴滢, 王雪莉, 王庆煜, 王文婷, 李治, 张彬, 金晶. 8例儿童卵巢颗粒细胞瘤临床病理特征及预后分析[J]. 上海交通大学学报(医学版), 2022, 42(2): 192-196.
[6]	林艳艳, 许岩, 李慧. 儿童急性淋巴细胞白血病化学治疗常规药物耐药机制的研究进展[J]. 上海交通大学学报(医学版), 2022, 42(2): 211-217.
[7]	孙元青, 徐韬, 张虓宇, 徐子锋, 柴静. 罗哌卡因联合单次小剂量艾司氯胺酮用于择期剖宫产脊椎麻醉的双盲序贯研究[J]. 上海交通大学学报（医学版）, 2022, 42(10): 1428-1434.
[8]	李爱求, 张潇潇, 姜允丽, 肖艳赏, 丁国栋, 吴蓓蓉, 董晓艳. 学龄前儿童反复喘息的相关危险因素分析[J]. 上海交通大学学报（医学版）, 2022, 42(10): 1435-1440.
[9]	吴雷, 杜重临, 夏一梦. 金喉健喷雾剂和利多卡因气雾剂在全身麻醉气管插管中的应用比较[J]. 上海交通大学学报(医学版), 2022, 42(1): 90-94.
[10]	刘青, 张娜, 邵静波, 李红, 陈凯, 杜成坎, 王真, 蒋慧. MLL基因重排阳性的儿童急性白血病患者的临床特点及预后分析[J]. 上海交通大学学报(医学版), 2021, 41(7): 903-909.
[11]	刘子豪, 唐文芳, 王辉. 儿童脑肿瘤氨基酸PET显像的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(7): 949-952.
[12]	陈博, 赵鹏军. 儿童室性早搏诱发心肌病的危险因素及其干预策略[J]. 上海交通大学学报(医学版), 2021, 41(7): 977-981.
[13]	朱嘉莳, 李红, 邵静波, 张娜, 杨静薇, 陈凯, 王真, 蒋慧. 急性淋巴细胞白血病儿童治疗失败原因的分析[J]. 上海交通大学学报(医学版), 2021, 41(6): 764-769.
[14]	王凤乔, 庄蕾, 张富军. 儿童疼痛记忆的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(4): 546-549.
[15]	周丝丝, 巩格言, 马佳莉, 高雯颖, 张莹. 慢性肾脏病患儿-家长过渡期准备与双方生活质量的互依关系分析[J]. 上海交通大学学报(医学版), 2021, 41(12): 1588-1595.